ClinVar Miner

Submissions for variant NM_000152.5(GAA):c.1124G>A (p.Arg375His)

gnomAD frequency: 0.00006  dbSNP: rs142752477
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000694178 SCV000822610 pathogenic Glycogen storage disease, type II 2023-10-28 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 375 of the GAA protein (p.Arg375His). This variant is present in population databases (rs142752477, gnomAD 0.02%). This missense change has been observed in individual(s) with Pompe disease (PMID: 21484825, 21757382; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 572725). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GAA protein function with a positive predictive value of 95%. This variant disrupts the p.Arg375 amino acid residue in GAA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 18429042, 22990675, 24158270, 29422078). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard RCV000694178 SCV001422740 uncertain significance Glycogen storage disease, type II 2020-01-22 criteria provided, single submitter curation The p.Arg375His variant in GAA has been reported in two Asian individuals with glycogen storage disease II (PMID: 21757382, 21484825), and has been reported in 0.02% of African chromosomes, 0.01% (3/30544) of South Asian chromosomes, and 0.0008% (1/127354) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs142752477). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar as a VUS by Invitae (VariationID: 572725). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. One additional likely pathogenic variant, resulting in a different amino acid change at the same position, p.Arg375Leu, has been reported in association with the disease in the literature and ClinVar (PMID: 25103075, 18429042, 18429042; VariationID: 283230). The phenotype of a heterozygous individual is highly specific for Glycogen Storage Disease II based on GAA activity assays with fibroblast cells (PMID: 21757382). In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM5_supporting, PM2, PP3, PP4 (Richards 2015).
Mayo Clinic Laboratories, Mayo Clinic RCV001507901 SCV001713735 likely pathogenic not provided 2020-12-16 criteria provided, single submitter clinical testing PM2, PM5, PP3, PP4
Genome-Nilou Lab RCV000694178 SCV001810593 likely pathogenic Glycogen storage disease, type II 2021-07-22 criteria provided, single submitter clinical testing
GeneDx RCV001507901 SCV001822697 pathogenic not provided 2020-11-17 criteria provided, single submitter clinical testing Previously reported in association with late-onset GSDII (Bali et al., 2011; Yang et al., 2011); Enzyme activity analysis confirmed a patient harboring R375H and an additional GAA variant had less than 1% GAA enzyme activity (Bali et al., 2011); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 33202836, 30275481, 21484825, 21757382)
Revvity Omics, Revvity RCV001507901 SCV003810575 uncertain significance not provided 2022-01-06 criteria provided, single submitter clinical testing
Baylor Genetics RCV000694178 SCV004197825 pathogenic Glycogen storage disease, type II 2023-05-25 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.